Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CanSino Biologics, Inc. Class H (HK:6185)
HKEX:6185
CanSino Biologics, Inc. Class H (6185) Stock Price & Analysis
0 Followers
6185 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$14.80 - HK$33.20
Previous CloseHK$19.78
Volume682.00K
Average Volume (3M)1.25M
Market Cap
HK$6.43B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 23, 2024EPS Estimate
-HK$0.4Last Dividend Ex-Date
Jul 13, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding132,670,900
10 Day Avg. Volume1,344,890
30 Day Avg. Volume1,246,318
Standard Deviation0.20
R-Squared0.00217
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CanSino Biologics, Inc. Class H News
PremiumCompany Announcements
CanSino Biologics Announces Board Structure
PremiumCompany Announcements
CanSino Biologics’ Resolutions Passed at AGM
PremiumCompany Announcements
CanSino Executives Plan to Boost Shareholdings
PremiumCompany Announcements
CanSino Biologics Announces Upcoming AGM AgendaPremiumCompany Announcements
CanSino Biologics Announces Board ChangesPremiumCompany Announcements
CanSino Biologics Unveils Board StructureOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
8.65% Mutual Funds
2.60% Other Institutional Investors
88.75% Public Companies and
Individual Investors
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$14.80 and its highest was HK$33.20 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
Currently, no data Available
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Aug 23, 2024 which is in 48 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Apr 29, 2024. The company reported -HK$0.741 earnings per share for the quarter, missing the consensus estimate of -HK$0.35 by -HK$0.391.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Overvalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.94 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate is -HK$0.4.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of -HK$0.741 in its last earnings report, missing expectations of -HK$0.35. Following the earnings report the stock price went down -0.106%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
---
CanSino Biologics, Inc. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.47%
12-Months-Change
Fundamentals
Return on Equity
-25.41%
Trailing 12-Months
Asset Growth
-27.58%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
---
6185 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
China Feihe Limited
―
BeiGene Ltd
―
Petro-king Oilfield Services Ltd.
―
Bank of Guizhou Co. Ltd. Class H
―
Best Analysts Covering 6185
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-19.10%
reiterated a buy rating 9 months ago
Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.10% per trade.
---